354 related articles for article (PubMed ID: 2385731)
41. Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: a case report.
Clayton RN; Webb J; Heath DA; Dunn PJ; Rolfe EB; Hockley AD
Clin Endocrinol (Oxf); 1985 May; 22(5):573-81. PubMed ID: 4028456
[TBL] [Abstract][Full Text] [Related]
42. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
[TBL] [Abstract][Full Text] [Related]
43. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
[TBL] [Abstract][Full Text] [Related]
44. Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas.
Mbanya JC; Mendelow AD; Crawford PJ; Hall K; Dewar JH; Kendall-Taylor P
Br J Neurosurg; 1993; 7(5):519-27. PubMed ID: 8267889
[TBL] [Abstract][Full Text] [Related]
45. Giant prolactinomas in women.
Delgrange E; Raverot G; Bex M; Burman P; Decoudier B; Devuyst F; Feldt-Rasmussen U; Andersen M; Maiter D
Eur J Endocrinol; 2014 Jan; 170(1):31-8. PubMed ID: 24088550
[TBL] [Abstract][Full Text] [Related]
46. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.
Leong KS; Foy PM; Swift AC; Atkin SL; Hadden DR; MacFarlane IA
Clin Endocrinol (Oxf); 2000 Jan; 52(1):43-9. PubMed ID: 10651752
[TBL] [Abstract][Full Text] [Related]
47. Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study.
Liu X; Liu Y; Gao J; Feng M; Bao X; Deng K; Yao Y; Wang R
World Neurosurg; 2018 Jul; 115():94-98. PubMed ID: 29530699
[TBL] [Abstract][Full Text] [Related]
48. [Long-term bromocriptine treatment of giant prolactinoma: report of a case].
Mashio Y; Beniko M; Ikota A; Mizumoto H; Sato S; Yamaguchi O; Suzuki S; Tashiro T; Ikota T
Nihon Naika Gakkai Zasshi; 1989 Dec; 78(12):1785-6. PubMed ID: 2625603
[No Abstract] [Full Text] [Related]
49. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
50. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
Lloyd HM; Jacobi JM; Willgoss DA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
[TBL] [Abstract][Full Text] [Related]
51. Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas.
Perrin G; Treluyer C; Trouillas J; Sassolas G; Goutelle A
Pathol Res Pract; 1991 Jun; 187(5):587-92. PubMed ID: 1923955
[TBL] [Abstract][Full Text] [Related]
52. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension.
van 't Verlaat JW; Croughs RJ; Hendriks MJ; Bosma NJ
Can J Neurol Sci; 1990 Feb; 17(1):71-3. PubMed ID: 2311021
[TBL] [Abstract][Full Text] [Related]
53. [A case of prolactinoma presenting with CSF rhinorrhea and CSF otorrhea during bromocriptine therapy].
Nakajima T; Tamura T; Kuroki M; Tanaka R; Hayashi H
No Shinkei Geka; 1992 Oct; 20(10):1091-5. PubMed ID: 1407345
[TBL] [Abstract][Full Text] [Related]
54. Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.
Jaspers C; Benker G; Reinwein D
Clin Investig; 1994 Jun; 72(6):451-6. PubMed ID: 7950157
[TBL] [Abstract][Full Text] [Related]
55. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
56. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment.
Saeki N; Nakamura M; Sunami K; Yamaura A
Endocr J; 1998 Aug; 45(4):529-37. PubMed ID: 9881903
[TBL] [Abstract][Full Text] [Related]
57. Giant prolactinomas presenting as skull base tumors.
Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
[TBL] [Abstract][Full Text] [Related]
58. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
Passos VQ; Souza JJ; Musolino NR; Bronstein MD
J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
[TBL] [Abstract][Full Text] [Related]
59. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.
Delgrange E; Trouillas J; Maiter D; Donckier J; Tourniaire J
J Clin Endocrinol Metab; 1997 Jul; 82(7):2102-7. PubMed ID: 9215279
[TBL] [Abstract][Full Text] [Related]
60. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]